Beta Bionics, Inc. Research and Development Expense
Beta Bionics, Inc. (BBNX) reported Research and Development Expense of $10.24 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-29.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-07-29
- Beta Bionics, Inc. research and development expense for the quarter ending 2026-06-30 was $10.24M, a 15.41% increase year-over-year.
- Beta Bionics, Inc. research and development expense for the quarter ending 2026-03-31 was $10.36M, a 36.44% increase year-over-year.
- Beta Bionics, Inc. research and development expense for the quarter ending 2025-12-31 was $10.13M, a 9.95% increase year-over-year.
- Beta Bionics, Inc. research and development expense for the quarter ending 2025-09-30 was $8.20M, a 59.40% increase year-over-year.
- Beta Bionics, Inc. research and development expense for fiscal 2025 was $34.79M, a 32.86% increase from fiscal 2024.
- Beta Bionics, Inc. research and development expense for fiscal 2024 was $26.18M, a 45.93% increase from fiscal 2023.
- Beta Bionics, Inc. research and development expense for fiscal 2023 was $17.94M.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $10.24M 10-Q · filed 2026-07-29 | $20.60M 10-Q · filed 2026-07-29 | $30.73M derived: sum of 3 quarters · filed 2026-07-29 | $38.92M derived: sum of 4 quarters · filed 2026-07-29 |
| 2026-03-31 | $10.36M 10-Q · filed 2026-04-21 | $20.49M derived: sum of 2 quarters · filed 2026-04-21 | $28.68M derived: sum of 3 quarters · filed 2026-04-21 | $37.55M derived: sum of 4 quarters · filed 2026-07-29 |
| 2025-12-31 | $10.13M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $18.33M derived: sum of 2 quarters · filed 2026-02-24 | $27.20M derived: sum of 3 quarters · filed 2026-07-29 | $34.79M 10-K · filed 2026-02-24 |
| 2025-09-30 | $8.20M 10-Q · filed 2025-10-28 | $17.07M derived: sum of 2 quarters · filed 2026-07-29 | $24.66M 10-Q · filed 2025-10-28 | $33.87M derived: sum of 4 quarters · filed 2026-07-29 |
| 2025-06-30 | $8.87M 10-Q · filed 2026-07-29 | $16.46M 10-Q · filed 2026-07-29 | $25.68M derived: sum of 3 quarters · filed 2026-07-29 | $30.82M derived: sum of 4 quarters · filed 2026-07-29 |
| 2025-03-31 | $7.59M 10-Q · filed 2026-04-21 | $16.80M derived: sum of 2 quarters · filed 2026-04-21 | $21.95M derived: sum of 3 quarters · filed 2026-04-21 | $28.30M derived: sum of 4 quarters · filed 2026-04-21 |
| 2024-12-31 | $9.21M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $14.36M derived: sum of 2 quarters · filed 2026-02-24 | $20.70M derived: sum of 3 quarters · filed 2026-02-24 | $26.18M 10-K · filed 2026-02-24 |
| 2024-09-30 | $5.14M 10-Q · filed 2025-10-28 | $11.49M derived: sum of 2 quarters · filed 2025-10-28 | $16.97M 10-Q · filed 2025-10-28 | |
| 2024-06-30 | $6.35M 10-Q · filed 2025-07-29 | $11.83M 10-Q · filed 2025-07-29 | ||
| 2024-03-31 | $5.48M 10-Q · filed 2025-05-06 | |||
| 2023-12-31 | $17.94M 10-K/A · filed 2025-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PROCEPT BioRobotics Corp (PRCT) | United States | $1.001B | -11.77 |
| SpyGlass Pharma, Inc. (SGP) | United States | $0.925B | |
| TANDEM DIABETES CARE INC (TNDM) | United States | $1.059B | -16.57 |
| IRADIMED CORP (IRMD) | United States | $1.089B | 52.92 |
| ARTIVION, INC. (AORT) | United States | $1.123B | -345.09 |
| SI-BONE, Inc. (SIBN) | United States | $0.830B | -49.82 |
| INTEGRA LIFESCIENCES HOLDINGS CORP (IART) | United States | $1.234B | -193.02 |
| MIMEDX GROUP, INC. (MDXG) | United States | $0.687B | 89.92 |
| ANGIODYNAMICS INC (ANGO) | United States | $0.632B | -13.02 |
| ORTHOPEDIATRICS CORP (KIDS) | United States | $0.592B |